Lymphohistiocytosis, Hemophagocytic [clinicaltrials_resource:9a6a5fc3e2c9c1b61c25a9010940b217]
condition [clinicaltrials_vocabulary:condition]
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies [clinicaltrials:NCT00006054]Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders [clinicaltrials:NCT00006056]clinicaltrials:NCT00176826Stem Cell Transplant for Immunologic or Histiocytic Disorders [clinicaltrials:NCT00176865]Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis [clinicaltrials:NCT00334672]clinicaltrials:NCT00368355clinicaltrials:NCT00426101Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders [clinicaltrials:NCT00895271]New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome [clinicaltrials:NCT01095146]clinicaltrials:NCT01104025Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity [clinicaltrials:NCT01125319]clinicaltrials:NCT01494103clinicaltrials:NCT01547143Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies [clinicaltrials:NCT01652092]A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis [clinicaltrials:NCT01818492]clinicaltrials:NCT01818908Immune Disorder HSCT Protocol [clinicaltrials:NCT01821781]clinicaltrials:NCT01917708CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease [clinicaltrials:NCT01966367]clinicaltrials:NCT01998633clinicaltrials:NCT02007239Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody [clinicaltrials:NCT02069899]clinicaltrials:NCT02113917Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases [clinicaltrials:NCT02231710]Alemtuzumab in Combination With Etoposide and Dexamethasone [clinicaltrials:NCT02385110]A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome [clinicaltrials:NCT02400463]clinicaltrials:NCT02472054
condition browse [clinicaltrials_vocabulary:condition-browse]
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies [clinicaltrials:NCT00006054]Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders [clinicaltrials:NCT00006056]clinicaltrials:NCT00176826Stem Cell Transplant for Immunologic or Histiocytic Disorders [clinicaltrials:NCT00176865]Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis [clinicaltrials:NCT00334672]clinicaltrials:NCT00368355clinicaltrials:NCT00426101Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders [clinicaltrials:NCT00895271]New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome [clinicaltrials:NCT01095146]clinicaltrials:NCT01104025Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity [clinicaltrials:NCT01125319]clinicaltrials:NCT01494103clinicaltrials:NCT01547143Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies [clinicaltrials:NCT01652092]A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis [clinicaltrials:NCT01818492]clinicaltrials:NCT01818908Immune Disorder HSCT Protocol [clinicaltrials:NCT01821781]clinicaltrials:NCT01917708CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease [clinicaltrials:NCT01966367]clinicaltrials:NCT01998633clinicaltrials:NCT02007239Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody [clinicaltrials:NCT02069899]clinicaltrials:NCT02113917Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases [clinicaltrials:NCT02231710]Alemtuzumab in Combination With Etoposide and Dexamethasone [clinicaltrials:NCT02385110]A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome [clinicaltrials:NCT02400463]clinicaltrials:NCT02472054
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Lymphohistiocytosis, Hemophagocytic [clinicaltrials_resource:9a6a5fc3e2c9c1b61c25a9010940b217]
Bio2RDF identifier
9a6a5fc3e2c9c1b61c25a9010940b217
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:9a6a5fc3e2c9c1b61c25a9010940b217
identifier
clinicaltrials_resource:9a6a5fc3e2c9c1b61c25a9010940b217
title
Lymphohistiocytosis, Hemophagocytic
@en
type
label
Lymphohistiocytosis, Hemophago ...... a5fc3e2c9c1b61c25a9010940b217]
@en
Lymphohistiocytosis, Hemophagocytic